Related Experiment Videos
Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)
P Büchler1, H A Reber, M C Büchler
1Department of Surgery, UCLA School of Medicine, Los Angeles, Calif 90095-6904, USA.
Abstract:
The HER2/neu oncogene is overexpressed in human pancreatic cancer, but the clinical significance of that overexpression is uncertain. In the present study we investigated the antitumor efficacy of Herceptin, a new recombinant humanized anti-HER2/neu antibody, which exhibits cytostatic activity on breast and prostate cancer cells that overexpress the HER2 oncogene. That antibody may retard tumor growth in certain patients with those diseases. We quantified HER2 expression in various human pancreatic cancer cell lines and studied the bioactivity of this antibody both in vitro and in vivo. Growth inhibition by Herceptin was observed in vitro in cell lines with high levels of HER2/neu expression. Cell lines with low levels of this protein did not respond significantly to the antibody. In vivo we studied two different pancreatic cancer cell lines in an orthotopic mouse model of the disease. Herceptin treatment suppressed tumor growth in the MIA PaCa-2 tumor cell line, which expressed high levels of HER2/neu. These data suggest that Herceptin treatment of patients with pancreatic cancer who express high levels of the HER2/neu oncogene may be reasonable.
Insights
Herceptin effectively inhibited pancreatic cancer cell growth in vitro and suppressed tumor growth in vivo for HER2/neu-positive cell lines. These findings suggest potential efficacy for Herceptin in treating HER2/neu-overexpressing pancreatic cancers.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- HER2/neu oncogene overexpression is observed in human pancreatic cancer.
- The clinical significance of HER2/neu overexpression in pancreatic cancer remains unclear.
- Herceptin, an anti-HER2/neu antibody, shows efficacy in other cancers overexpressing HER2/neu.
Purpose of the Study:
- To investigate the antitumor efficacy of Herceptin in human pancreatic cancer.
- To determine the correlation between HER2/neu expression levels and Herceptin response.
- To evaluate Herceptin's bioactivity in vitro and in vivo models of pancreatic cancer.
Main Methods:
- Quantification of HER2/neu expression in human pancreatic cancer cell lines.
- In vitro assessment of Herceptin's effect on cancer cell growth.
- In vivo evaluation of Herceptin's efficacy using an orthotopic mouse model with pancreatic cancer cell lines.
Main Results:
- Herceptin demonstrated significant growth inhibition in vitro for pancreatic cancer cell lines with high HER2/neu expression.
- Cell lines with low HER2/neu expression showed minimal response to Herceptin.
- In vivo, Herceptin treatment suppressed tumor growth in the MIA PaCa-2 cell line, which exhibits high HER2/neu expression.
Conclusions:
- Pancreatic cancer cell growth can be inhibited by Herceptin, particularly in cell lines with high HER2/neu expression.
- Herceptin shows potential as a therapeutic agent for pancreatic cancer patients with high HER2/neu oncogene expression.
- Further investigation into Herceptin's role in pancreatic cancer treatment is warranted.